• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

荷兰保乳治疗乳腺导管原位癌的侵袭性复发:时间趋势及与肿瘤分级的关系。

Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.

机构信息

Department of Epidemiology, Maastricht University, Maastricht, Netherlands.

Department of Radiology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands.

出版信息

Br J Cancer. 2024 Sep;131(5):852-859. doi: 10.1038/s41416-024-02785-6. Epub 2024 Jul 9.

DOI:10.1038/s41416-024-02785-6
PMID:38982194
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11369187/
Abstract

BACKGROUND

The first aim of this study was to examine trends in the risk of ipsilateral invasive breast cancer (iIBC) after breast-conserving surgery (BCS) of ductal carcinoma in situ (DCIS). A second aim was to analyse the association between DCIS grade and the risk of iIBC following BCS.

PATIENTS AND METHODS

In this population-based, retrospective cohort study, the Netherlands Cancer Registry collected information on 25,719 women with DCIS diagnosed in the period 1989-2021 who underwent BCS. Of these 19,034 received adjuvant radiotherapy (RT). Kaplan-Meier analyses and Cox regression models were used.

RESULTS

A total of 1135 patients experienced iIBC. Ten-year cumulative incidence rates of iIBC for patients diagnosed in the periods 1989-1998, 1999-2008 and 2009-2021 undergoing BCS without RT, were 12.6%, 9.0% and 5.0% (P < 0.001), respectively. For those undergoing BCS with RT these figures were 5.7%, 3.7% and 2.2%, respectively (P < 0.001). In the multivariable analyses, DCIS grade was not associated with the risk of iIBC.

CONCLUSION

Since 1989 the risk of iIBC has decreased substantially and has become even lower than the risk of invasive contralateral breast cancer. No significant association of DCIS grade with iIBC was found, stressing the need for more powerful prognostic factors to guide the treatment of DCIS.

摘要

背景

本研究的首要目的是探讨保乳手术后(BCS)导管原位癌(DCIS)同侧浸润性乳腺癌(iIBC)的风险趋势。第二个目的是分析 DCIS 分级与 BCS 后 iIBC 风险之间的关联。

患者和方法

在这项基于人群的回顾性队列研究中,荷兰癌症登记处收集了 1989 年至 2021 年期间接受 BCS 治疗的 25719 名 DCIS 女性患者的信息。其中 19034 名患者接受了辅助放疗(RT)。使用 Kaplan-Meier 分析和 Cox 回归模型。

结果

共有 1135 例患者发生 iIBC。未接受 RT 的 BCS 患者在 1989-1998 年、1999-2008 年和 2009-2021 年诊断的患者 10 年 iIBC 累积发生率分别为 12.6%、9.0%和 5.0%(P<0.001)。接受 RT 的 BCS 患者的这些数据分别为 5.7%、3.7%和 2.2%(P<0.001)。在多变量分析中,DCIS 分级与 iIBC 风险无关。

结论

自 1989 年以来,iIBC 的风险已大幅降低,甚至低于浸润性对侧乳腺癌的风险。未发现 DCIS 分级与 iIBC 之间存在显著关联,这强调需要更强大的预后因素来指导 DCIS 的治疗。

相似文献

1
Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.荷兰保乳治疗乳腺导管原位癌的侵袭性复发:时间趋势及与肿瘤分级的关系。
Br J Cancer. 2024 Sep;131(5):852-859. doi: 10.1038/s41416-024-02785-6. Epub 2024 Jul 9.
2
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.乳腺导管原位癌:发病率、治疗和结局的系统评价。
J Natl Cancer Inst. 2010 Feb 3;102(3):170-8. doi: 10.1093/jnci/djp482. Epub 2010 Jan 13.
3
A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation Therapy.一种用于乳腺导管原位癌的7基因生物标志物可识别保乳手术和放疗后复发率不同的HER2阳性患者亚群。
Clin Breast Cancer. 2025 Feb;25(2):e152-e158.e1. doi: 10.1016/j.clbc.2024.08.016. Epub 2024 Sep 4.
4
Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study.局部区域治疗后导管原位癌患者的疾病特异性生存结果:观察性队列研究。
Br J Surg. 2024 Aug 30;111(9). doi: 10.1093/bjs/znae198.
5
Post-operative radiotherapy for ductal carcinoma in situ of the breast.乳腺导管原位癌的术后放疗
Cochrane Database Syst Rev. 2009 Oct 7(4):CD000563. doi: 10.1002/14651858.CD000563.pub6.
6
Post-operative radiotherapy for ductal carcinoma in situ of the breast.乳腺导管原位癌的术后放疗
Cochrane Database Syst Rev. 2009 Jul 8(3):CD000563. doi: 10.1002/14651858.CD000563.pub5.
7
Post-operative radiotherapy for ductal carcinoma in situ of the breast.乳腺导管原位癌的术后放疗
Cochrane Database Syst Rev. 2009 Jan 21(1):CD000563. doi: 10.1002/14651858.CD000563.pub4.
8
The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population.当代治疗 DCIS 对荷兰人群同侧浸润性乳腺癌 (iIBC) 发病风险的影响。
Breast Cancer Res Treat. 2024 Feb;204(1):61-68. doi: 10.1007/s10549-023-07168-8. Epub 2023 Nov 14.
9
Network meta-analysis of margin threshold for women with ductal carcinoma in situ.网络荟萃分析女性导管原位癌的切缘阈值。
J Natl Cancer Inst. 2012 Apr 4;104(7):507-16. doi: 10.1093/jnci/djs142. Epub 2012 Mar 22.
10
Clinicopathologic characteristics of ductal carcinoma in situ and risk of subsequent invasive breast cancer: a multicenter, population-based cohort study.导管原位癌的临床病理特征及后续浸润性乳腺癌的风险:一项基于人群的多中心队列研究
Breast Cancer Res Treat. 2025 Apr;210(3):615-625. doi: 10.1007/s10549-024-07599-x. Epub 2025 Jan 20.

引用本文的文献

1
Does grade matter? Evaluation of histologic grade in patients with stage 1 non-small cell lung cancer using the National Cancer Database.分级重要吗?利用国家癌症数据库对Ⅰ期非小细胞肺癌患者的组织学分级进行评估。
JTCVS Open. 2025 Mar 11;25:393-405. doi: 10.1016/j.xjon.2025.02.017. eCollection 2025 Jun.

本文引用的文献

1
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.DCIS 大小和边缘状态与治疗后乳腺癌发病风险的关系:多国、汇总队列研究。
BMJ. 2023 Oct 30;383:e076022. doi: 10.1136/bmj-2023-076022.
2
Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer.高危乳腺病变或乳腺原位癌诊断后的一级和二级预防内分泌治疗。
J Clin Oncol. 2023 Jun 10;41(17):3092-3099. doi: 10.1200/JCO.23.00455. Epub 2023 May 1.
3
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.随机安慰剂对照试验低剂量他莫昔芬预防乳腺非浸润性肿瘤复发:TAM-01 研究的 10 年随访。
J Clin Oncol. 2023 Jun 10;41(17):3116-3121. doi: 10.1200/JCO.22.02900. Epub 2023 Mar 14.
4
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.在非低危型乳腺导管原位癌(BIG 3-07/TROG 07.01)中,放射剂量和分割方案:一项随机、析因、多中心、开放标签、III 期研究。
Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6.
5
Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study.未切除的筛检性导管原位癌:Forget-Me-Not 2 研究中 311 名女性的结局。
Breast. 2022 Feb;61:145-155. doi: 10.1016/j.breast.2022.01.001. Epub 2022 Jan 4.
6
Variability in grading of ductal carcinoma in situ among an international group of pathologists.国际病理学家小组中导管原位癌分级的变异性。
J Pathol Clin Res. 2021 May;7(3):233-242. doi: 10.1002/cjp2.201. Epub 2021 Feb 23.
7
Deep learning-based grading of ductal carcinoma in situ in breast histopathology images.基于深度学习的乳腺组织病理图像导管原位癌分级。
Lab Invest. 2021 Apr;101(4):525-533. doi: 10.1038/s41374-021-00540-6. Epub 2021 Feb 19.
8
Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands.荷兰导管原位癌的治疗模式和结局。
Breast Cancer Res Treat. 2021 May;187(1):245-254. doi: 10.1007/s10549-020-06055-w. Epub 2021 Jan 1.
9
Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.11337 例原发性导管原位癌(DCIS)患者的病理特征及后续事件:来自英国斯隆项目的结果。
Br J Cancer. 2021 Mar;124(5):1009-1017. doi: 10.1038/s41416-020-01152-5. Epub 2020 Nov 17.
10
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.每周 1 周与 3 周(FAST-Forward)的分割式乳房放射治疗:来自多中心、非劣效性、随机、3 期试验的 5 年疗效和晚期正常组织效应结果。
Lancet. 2020 May 23;395(10237):1613-1626. doi: 10.1016/S0140-6736(20)30932-6. Epub 2020 Apr 28.